Mobile imaging provider Alliance Imaging, of Orange, CA, turnedin strong revenue and net income numbers for 1996 (end-December).The company said that its debt restructuring is nearly complete,which will enable Alliance to accelerate its growth plan.For
Mobile imaging provider Alliance Imaging, of Orange, CA, turnedin strong revenue and net income numbers for 1996 (end-December).The company said that its debt restructuring is nearly complete,which will enable Alliance to accelerate its growth plan.
For the year, Alliance posted revenues of $68.5 million, up 18%compared with revenues of $58.1 million in 1995. Net income morethan tripled to $12.8 million, compared with $4.1 million theyear before. While last year's net income numbers were helpedby a $6.3 million one-time gain, Alliance's income before extraordinarygains was $6.5 million for 1996, still a big jump from the previousyear.
Alliance exceeded its goals in 1996, according to Richard Zehner,chairman, president, and CEO. Zehner said that the company's purchaseof new scanners, coupled with several acquisitions of smallerimaging providers, helped it generate a big increase in the numberof scans it performed last year.
In other Alliance news, the company continued its scanner purchaseprogram this month, taking delivery of four new 1-tesla MRI scannersmanufactured by GE Medical Systems in an order valued at $7 million.Alliance plans to take delivery of three more GE scanners andthree Siemens magnets in the second quarter, the company said.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.